many new drug studies abroad adopt this model, which is developed by independent laboratories, and may also include pharmacological, toxicological, and other non-clinical studies. In the near future, the patents for this drug may be acquired by large pharmaceutical companies and invested by large enterprises in clinical research.
this model has actually changed large enterprises from pure R & D model to investment R & D model. The majority of drug R & D investment is in the clinical research stage. At present, most of the clinical research investment in new drugs in the world is more than 1 billion US dollars (although some insiders point out that such data are hydrated). Independent laboratories basically do not have the ability to invest in their own research, and large enterprises can be freed from computer screening compounds, just looking for promising compounds in the laboratory.
back to the event described in the news, judging from the contents of the press release, Fudan University's role in the development of the compound is equivalent to an independent laboratory, and if further clinical research is to be carried out, it will require a sky-high investment. According toexclusive: annual scientific research funding list of Chinese universities!according to the content of this news, the scientific research funding of Fudan University in 2014 is only more than 2 billion soft girls, that is, the scientific research funding of the whole university is not enough to burn this new drug. In this case, Fudan University continues to carry out research, which is called"making things with taxpayers' money."
so why not sell it to Chinese companies?
seeWhy does China rarely have its own innovative drugs?
according to the data provided in this answer, 67 Chinese pharmaceutical enterprises invested in R & D in 2014 were announced. In other words, the 67 companies together are not enough to develop the new drug.
and there are still a considerable number of clinical trial institutions in China there are non-standard management, data fraud, China's CFDA in the global FDA prestige is not too high, in this case, sold to Chinese enterprises for clinical research, is likely to! Lost! Defeat! (of course, selling to foreign companies is also at risk of failure) if it fails, all the previous research has been wasted.
therefore, Fudan University does not sell this compound to domestic enterprises because domestic enterprises cannot invest so much R & D funds and have no R & D capability, and there are too many domestic pharmaceutical companies. According to the statistics before the implementation of the new version of GMP in 2013, there are more than 6000, this small-scale decentralized way has increased vicious competition among peers, and is not conducive to the research of new drugs. At present, some Chinese pharmaceutical companies in Jiangsu and other places have begun to attach importance to new drug research and development, and have achieved some results, but there is still a long way to go to catch up with such giants as Pfizer, Roche, and so on.
finally, I had no interest in Fudan University or the research project team, so there was no question of whether to wash the land or not. And I hate the word washing, spray people do not reply, report directly, thank you.